

Summary of status of development and availability of variant¹ influenza A(H3N2) candidate vaccine viruses and potency testing reagents

12 October 2018

Candidate vaccine viruses

Antigenic prototype	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Minnesota/11/2010	Wild type virus			WHO CCs
	NYMC X-203*	Classical	NYMC, USA	CDC, USA NYMC, USA
	NYMC X-203A*	Classical	NYMC, USA	CDC, USA NYMC, USA
A/Indiana/10/2011	Wild type virus			WHO CCs
	NYMC X-213*	Classical	NYMC, USA	CDC, USA NYMC, USA

*These viruses are candidate vaccine viruses which have passed relevant safety testing and two-way haemagglutination inhibition (HI) tests. They can be handled under BSL-2 enhanced containment².

Candidate vaccine viruses in preparation

Antigenic prototype	Type of virus or reassortant	Developing Institute	Available from
A/Ohio/28/2016	Classical	NIBSC, UK	Pending
	Reverse genetics	CDC, USA	Pending

Institutes contact details for candidate vaccine viruses orders/information:

CDC: dwentworth@cdc.gov (Subject: CVV request)

NIBSC: standards@nibsc.org or enquiries@nibsc.org

NYMC: doris_bucher@nymc.edu

WHO CCs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres/list/en/

For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to

<http://www.who.int/influenza/vaccines/virus/en/>

¹ Joint FAO, OIE, WHO announcement of the standardization of terminology for the variant A(H3N2) virus recently infecting humans at http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/

² <http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/Annex%205%20human%20pandemic%20influenza.pdf?ua=1>